This week in Other Barks & Bites: the U.S. Trade Representative issues its annual Special 301 Report listing the European ...

Alnylam Pharmaceuticals is well-positioned in the TTR amyloidosis market, with a robust franchise and reliable clinical asset ...

Vyndamax, which treats heart problems in adults with cardiomyopathy, along with its related drugs, generated $6.3 billion in ...

Pfizer Inc. (NYSE:PFE) is one of the most active US stocks to buy right now. On April 28, Pfizer entered into settlement ...

Pfizer has reached agreements with Dexcel Pharma, Hikma Pharmaceuticals and Cipla, regarding lawsuits filed in the U.S.

On April 28, Morgan Stanley reiterated an Equal Weight rating on Pfizer Inc. (NYSE:PFE). It also set a $28 price target on ...

Pfizer has settled patent disputes with Cipla, Dexcel Pharma, and Hikma Pharmaceuticals over Vyndamax, extending U.S.

Pfizer Inc. announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in the US District ...

Pfizer has reached settlements with three drugmakers to delay US generic competition for its $6.4 billion heart drug Vyndamax until 2031, extending revenue stability amid looming industry pressures.

BridgeBio Pharma, Inc. remains a Buy, driven by Attruby’s strong U.S. launch and favorable competitive dynamics. Learn more ...

In this article, we will discuss the 9 Most Active US Stocks to Buy Right Now. On April 29, Joe Amato, Neuberger President ...

Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.